SIMCERE PHARMAC. GRP LTD (S2P) — Capital Reinvestment Ratio
Latest as of December 2025:
0.43x
SIMCERE PHARMAC. GRP LTD (S2P) has a Capital Reinvestment Ratio of 0.43x as of December 2025, meaning it reinvests 0% of its operating cash flow (€2.01 Billion) in capital expenditures (€862.20 Million). See S2P free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.43x
Capex / Operating Cash Flow
Operating Cash Flow
€2.01 Billion
EUR
Capital Expenditures
€862.20 Million
EUR
Data as of
Dec 2025
Most recent filing
SIMCERE PHARMAC. GRP LTD Capital Reinvestment Ratio (2022–2025)
This chart tracks SIMCERE PHARMAC. GRP LTD's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for SIMCERE PHARMAC. GRP LTD (2022–2025)
Year-by-year Capital Reinvestment Ratio for SIMCERE PHARMAC. GRP LTD from 2022 to 2025. For live market cap and broader valuation context, see market value of SIMCERE PHARMAC. GRP LTD.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.43x | €2.01 Billion | €862.20 Million | ▼ -21.9% |
| 2024 | 0.55x | €1.39 Billion | €762.57 Million | ▼ -91.5% |
| 2023 | 6.49x | €151.05 Million | €979.86 Million | ▲ +1195.6% |
| 2022 | 0.50x | €1.35 Billion | €678.00 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow